DDR Biomarker
Cancers with DNA Damage Response vulnerabilities
Biomarker DevelopmentActive
Key Facts
Indication
Cancers with DNA Damage Response vulnerabilities
Phase
Biomarker Development
Status
Active
Company
About Genialis
Genialis is a Boston-based precision oncology company founded in 2015, focusing on using AI to de-risk and accelerate oncology drug development. Its core technology is the Genialis Supermodel, a foundation AI model of cancer biology, supported by a multiomics data infrastructure called Genialis Expressions. The company provides therapeutic intelligence across the drug development lifecycle, aiming to improve patient stratification, understand drug mechanisms of action, and increase clinical trial success rates for its biopharma partners.
View full company profile